260 related articles for article (PubMed ID: 16461309)
21. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
22. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Moravcová J; Zmeková V; Klamová H; Voglová J; Faber E; Michalová K; Rabasová J; Jarosová M
Leuk Res; 2004 Apr; 28(4):415-9. PubMed ID: 15109543
[TBL] [Abstract][Full Text] [Related]
23. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
24. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
25. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
Agirre X; Fontalba A; Andreu EJ; Odero MD; Larráyoz MJ; Montiel C; Calasanz MJ; Fernández-Luna JL; Prósper F
Haematologica; 2003 Dec; 88(12):1425-6. PubMed ID: 14687999
[No Abstract] [Full Text] [Related]
26. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
27. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
28. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
29. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
30. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Khorashad JS; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo JV; Goldman JM; Apperley JF; Kaeda J
Leukemia; 2006 Apr; 20(4):658-63. PubMed ID: 16467863
[TBL] [Abstract][Full Text] [Related]
31. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
Galimberti S; Cervetti G; Guerrini F; Testi R; Pacini S; Fazzi R; Simi P; Petrini M
Cancer Genet Cytogenet; 2005 Oct; 162(1):57-62. PubMed ID: 16157201
[TBL] [Abstract][Full Text] [Related]
32. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
33. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.
Roche-Lestienne C; Preudhomme C
Semin Hematol; 2003 Apr; 40(2 Suppl 2):80-2. PubMed ID: 12783380
[TBL] [Abstract][Full Text] [Related]
35. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
Cariani E; Capucci M; Micheletti M; Spalenza F; Zanella I; Albertini A; Rossi G
Ann Hematol; 2003 Jun; 82(6):333-5. PubMed ID: 12734675
[TBL] [Abstract][Full Text] [Related]
36. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
37. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
38. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.
Hayette S; Michallet M; Baille ML; Magaud JP; Nicolini FE
Leuk Res; 2005 Sep; 29(9):1073-7. PubMed ID: 16038734
[TBL] [Abstract][Full Text] [Related]
39. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
[TBL] [Abstract][Full Text] [Related]
40. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]